Benign Prostatic Hyperplasia, Metabolic Syndrome, and Androgenic Alopecia: Is There a Possible Relationship?

    February 2016 in “ Arab journal of urology ”
    Naglaa Agamia, Tamer Abou Youssif, Abeer E. El-Hadidy, Amr Magdy El-Abd
    Image of study
    TLDR People with early hair loss may have a higher chance of enlarged prostate and metabolic syndrome, so they should be checked for urinary and metabolic issues.
    The 2016 study with 400 participants explored the relationship between androgenetic alopecia (AGA), benign prostatic hyperplasia (BPH), and metabolic syndrome. It found that those with AGA had a higher incidence of metabolic syndrome (51% vs 28%) and BPH (36% vs 6.8%) compared to those without AGA. The AGA group also had significantly higher waist circumference, body mass index, fibrinogen level, fasting blood sugar, cholesterol, C-reactive protein, erythrocyte sedimentation rate, and glycosylated haemoglobin. The study concluded that both BPH and metabolic syndrome were significant independent variables associated with AGA, suggesting that patients with early-onset AGA should be monitored for urinary symptoms and metabolic syndrome symptoms for early diagnosis of BPH and cardiovascular risk factors respectively.
    Discuss this study in the Community →

    Research cited in this study

    10 / 10 results

    Related Community Posts Join

    6 / 1000+ results

      community Male pattern baldness, and mental health

      in Finasteride/Dutasteride  330 upvotes 9 months ago
      A 48-year-old man has been using minoxidil for 15 years and considered finasteride but stopped due to potential side effects. He is concerned about his mental health and the impact of hair loss on self-image, and he encourages support among men experiencing hair loss.

      community New and Interesting HairLoss Studies/Papers/Reviews

      in Treatment  44 upvotes 4 years ago
      Hair loss treatments discussed include Dutasteride with Ketoconazole, tissue engineering strategies, and androgenetic alopecia therapies. Massage doubles follicular retention, improving treatment effectiveness.
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 2 months ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

    Similar Research

    5 / 1000+ results